Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.8 EUR
191.04 M EUR
1.90 B EUR
170.94 M
About Rohto Pharmaceutical Co., Ltd.
Sector
Industry
CEO
Kunio Yamada
Website
Headquarters
Osaka
Founded
1949
IPO date
Oct 2, 1961
Identifiers
2
ISIN JP3982400008
Rohto Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products, cosmetics, and functional food items. Its products include eye drops, contact lens care, dermal medicines, skin care, internal medicines, cold remedies, test kits, and denture cleansers. Its operations are carried out through the following geographical segments: Japan, America, Europe, Asia, and Others. The company was founded by Anmin Yamada on February 22, 1899 and is headquartered in Osaka, Japan.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Rohto Pharmaceutical Co., Ltd. stocks are traded under the ticker UC1.
We've gathered analysts' opinions on Rohto Pharmaceutical Co., Ltd. future price: according to them, UC1 price has a max estimate of 18.48 EUR and a min estimate of 13.59 EUR. Watch UC1 chart and read a more detailed Rohto Pharmaceutical Co., Ltd. stock forecast: see what analysts think of Rohto Pharmaceutical Co., Ltd. and suggest that you do with its stocks.
Yes, you can track Rohto Pharmaceutical Co., Ltd. financials in yearly and quarterly reports right on TradingView.
Rohto Pharmaceutical Co., Ltd. is going to release the next earnings report on May 13, 2026. Keep track of upcoming events with our Earnings Calendar.
UC1 earnings for the last quarter are 0.26 EUR per share, whereas the estimation was 0.24 EUR resulting in a 6.62% surprise. The estimated earnings for the next quarter are 0.21 EUR per share. See more details about Rohto Pharmaceutical Co., Ltd. earnings.
Rohto Pharmaceutical Co., Ltd. revenue for the last quarter amounts to 482.52 M EUR, despite the estimated figure of 497.17 M EUR. In the next quarter, revenue is expected to reach 461.38 M EUR.
UC1 net income for the last quarter is 57.73 M EUR, while the quarter before that showed 33.90 M EUR of net income which accounts for 0.00% change. Track more Rohto Pharmaceutical Co., Ltd. financial stats to get the full picture.
Yes, UC1 dividends are paid semi-annually. The last dividend per share was 0.13 EUR. As of today, Dividend Yield (TTM)% is 1.80%. Tracking Rohto Pharmaceutical Co., Ltd. dividends might help you take more informed decisions.
Rohto Pharmaceutical Co., Ltd. dividend yield was 1.61% in 2024, and payout ratio reached 26.45%. The year before the numbers were 0.91% and 19.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 17, 2026, the company has 9.14 K employees. See our rating of the largest employees — is Rohto Pharmaceutical Co., Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Rohto Pharmaceutical Co., Ltd. EBITDA is 310.42 M EUR, and current EBITDA margin is 16.72%. See more stats in Rohto Pharmaceutical Co., Ltd. financial statements.
Like other stocks, UC1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Rohto Pharmaceutical Co., Ltd. stock right from TradingView charts — choose your broker and connect to your account.